MCID: OVR059
MIFTS: 49

Ovary Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma 12 15
Ovarian Adenocarcinoma 12 58 6 17 70
Adenocarcinoma of the Ovary 12
Adenocarcinoma of Ovary 58
Ovarian Adenoacanthoma 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3713
NCIt 50 C7700
ICD10 via Orphanet 33 C56
UMLS via Orphanet 71 C0948216
Orphanet 58 ORPHA213504
UMLS 70 C0948216

Summaries for Ovary Adenocarcinoma

Disease Ontology : 12 An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to endometrioid ovary carcinoma and clear cell adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is INHBA (Inhibin Subunit Beta A), and among its related pathways/superpathways are TGF-Beta Pathway and Toll-like Receptor Signaling Pathway. The drugs Paclitaxel and Nintedanib have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
# Related Disease Score Top Affiliating Genes
1 endometrioid ovary carcinoma 32.2 TP53 PIK3CA KRAS CTNNB1 ARID1A
2 clear cell adenocarcinoma 31.7 TP53 PIK3CA ARID1A
3 mucinous adenocarcinoma 31.6 TP53 KRAS ERBB2 CEACAM5
4 appendix adenocarcinoma 31.5 KRAS HRAS
5 ovarian clear cell adenocarcinoma 31.3 TP53 PIK3CA ARID1A
6 ovarian cystadenocarcinoma 31.2 TP53 SERPINA3 PIK3CA MIR744 MIR30A MIR17
7 papillary adenocarcinoma 31.2 TP53 MIR30A ERBB2 CEACAM5 BRCA1
8 adenofibroma 31.1 TP53 BRAF ARID1A
9 clear cell adenofibroma 31.0 PIK3CA ARID1A
10 serous cystadenocarcinoma 31.0 TP53 PIK3CA MIR30A KRAS HRAS ESS2
11 small cell carcinoma 30.9 TP53 KRAS ERBB2
12 papillary serous adenocarcinoma 30.8 TP53 MIR30A KRAS HRAS CEACAM5 BRCA1
13 pseudomyxoma peritonei 30.8 TP53 KRAS CTNNB1 CEACAM5
14 cystadenocarcinoma 30.7 TP53 SERPINA3 PIK3CA MIR30A HRAS ERBB2
15 adenoma 30.6 TP53 PIK3CA KRAS CTNNB1 BRAF
16 cystadenoma 30.6 SERPINA3 CEACAM5 BRCA1
17 teratoma 30.6 TP53 KRAS CTNNB1 CEACAM5
18 ovarian clear cell carcinoma 30.5 TP53 PIK3CA KRAS ARID1A
19 ovarian serous carcinoma 30.5 TP53 KRAS BRCA1
20 fallopian tube carcinoma 30.5 TP53 ERBB2 BRCA1
21 endometrial hyperplasia 30.5 TP53 KRAS CTNNB1 ARID1A
22 endocervical adenocarcinoma 30.5 TP53 PIK3CA ERBB2 CEACAM5
23 pilocytic astrocytoma 30.5 TP53 PIK3CA KRAS HRAS BRAF
24 rectum cancer 30.5 MIR17 KRAS HRAS CEACAM5
25 myoma 30.4 TP53 KRAS CEACAM5
26 adenosarcoma 30.4 TP53 SERPINA3 ERBB2
27 wolffian duct adenocarcinoma 30.4 KRAS HRAS
28 malignant astrocytoma 30.4 TP53 SERPINA3 MIR17 H2AC18 ERBB2 CTNNB1
29 squamous cell carcinoma 30.3 TP53 PIK3CA HRAS ERBB2 CTNNB1 CEACAM5
30 endometrial adenocarcinoma 30.3 TP53 KRAS ERBB2 CTNNB1
31 cervical squamous cell carcinoma 30.3 TP53 PIK3CA KRAS CTNNB1
32 colorectal adenocarcinoma 30.3 TP53 KRAS HRAS ERBB2 CTNNB1 CEACAM5
33 sarcoma 30.2 TP53 PIK3CA KRAS HRAS CTNNB1 BRAF
34 carcinosarcoma 30.2 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
35 ovarian disease 30.1 TP53 MIR30A MIR17 ERBB2 CTNNB1 BRCA1
36 cervical cancer 30.1 TP53 PIK3CA MIR17 HRAS ERBB2 CTNNB1
37 adenocarcinoma 30.1 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
38 peripheral nervous system disease 30.1 TP53 SERPINA3 MIR17 HRAS H2AC18 ERBB2
39 ovarian serous cystadenocarcinoma 30.1 TP53 SERPINA3 PIK3CA MIR744 MIR30A MIR17
40 endometrial cancer 30.1 TP53 SERPINA3 PIK3CA KRAS HRAS ERBB2
41 rhabdomyosarcoma 30.0 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
42 thyroid gland cancer 29.9 TP53 PIK3CA MIR17 KRAS HRAS ERBB2
43 esophageal cancer 29.9 TP53 PIK3CA MIR30A KRAS HRAS ERBB2
44 myeloma, multiple 29.9 TP53 PIK3CA MIR30A MIR17 KRAS HRAS
45 ovarian cancer 29.8 TP53 PIK3CA OVAAL MIR30A MIR17 KRAS
46 lynch syndrome 29.8 TP53 PIK3CA MIR17 KRAS HRAS H2AC18
47 skin melanoma 29.8 TP53 SERPINA3 PIK3CA KRAS HRAS H2AC18
48 hepatocellular carcinoma 29.7 TP53 PIK3CA MIR30A MIR17 KRAS HRAS
49 lung cancer susceptibility 3 29.6 TP53 PIK3CA MIR30A MIR17 KRAS HRAS
50 leukemia, acute myeloid 29.6 TP53 SERPINA3 PIK3CA MIR744 MIR30A MIR17

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:



Diseases related to Ovary Adenocarcinoma

Symptoms & Phenotypes for Ovary Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 76)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.46 KRAS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.46 BRCA1 PIK3CA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.46 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 10.46 C1RL
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-135 10.46 BRCA1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.46 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.46 PIK3CA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.46 PIK3CA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.46 KRAS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.46 PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.46 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.46 C1RL KRAS PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 10.46 BRCA1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.46 PIK3CA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.46 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.46 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.46 KRAS PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.46 KRAS
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.46 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.46 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.46 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.46 BRCA1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.46 C1RL KRAS PIK3CA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.46 BRCA1 KRAS
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.46 BRCA1 KRAS PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.46 C1RL
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.46 KRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.46 BRCA1
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.46 BRCA1
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.46 C1RL
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.46 KRAS
32 Decreased viability GR00055-A-1 10.05 BRAF HRAS KRAS PIK3CA
33 Decreased viability GR00055-A-2 10.05 BRAF HRAS KRAS PIK3CA
34 Decreased viability GR00055-A-3 10.05 KRAS
35 Decreased viability GR00106-A-0 10.05 KRAS
36 Decreased viability GR00221-A-1 10.05 HRAS KRAS PIK3CA
37 Decreased viability GR00221-A-2 10.05 HRAS KRAS PIK3CA
38 Decreased viability GR00221-A-3 10.05 HRAS
39 Decreased viability GR00221-A-4 10.05 BRAF PIK3CA
40 Decreased viability GR00249-S 10.05 BRAF
41 Decreased viability GR00301-A 10.05 BRAF KRAS
42 Decreased viability GR00381-A-1 10.05 BRAF KRAS
43 Decreased viability GR00402-S-2 10.05 PIK3CA
44 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.94 KRAS
45 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.94 C1RL
46 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.94 C1RL
47 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.94 BRCA1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.94 BRCA1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.94 BRAF
50 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.94 ERBB2

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.24 ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
2 integument MP:0010771 10.18 BRAF BRCA1 CTNNB1 ERBB2 HRAS INHBA
3 muscle MP:0005369 10.17 ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
4 embryo MP:0005380 10.16 ARID1A BRAF BRCA1 CTNNB1 ERBB2 INHBA
5 craniofacial MP:0005382 10.14 ARID1A BRAF CTNNB1 ERBB2 HRAS INHBA
6 digestive/alimentary MP:0005381 10.13 BRAF BRCA1 CTNNB1 ERBB2 HRAS INHBA
7 neoplasm MP:0002006 10.1 ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
8 limbs/digits/tail MP:0005371 10.06 BAX BRAF BRCA1 C1RL CTNNB1 ERBB2
9 normal MP:0002873 9.97 ARID1A BRAF BRCA1 CTNNB1 ERBB2 HRAS
10 no phenotypic analysis MP:0003012 9.91 ARID1A CTNNB1 ESS2 HRAS KRAS PIK3CA
11 renal/urinary system MP:0005367 9.86 BAX BRAF BRCA1 CTNNB1 HRAS INHBA
12 reproductive system MP:0005389 9.85 ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
13 respiratory system MP:0005388 9.56 BAX BRAF BRCA1 CTNNB1 ERBB2 HRAS
14 skeleton MP:0005390 9.4 ARID1A BAX BRAF BRCA1 C1RL CTNNB1

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Nintedanib Approved Phase 2 656247-17-5 56843413
3
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
4
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
5
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
6
Molgramostim Investigational Phase 2 99283-10-0
7 Albumin-Bound Paclitaxel Phase 2
8 Vaccines Phase 2
9 Adjuvants, Immunologic Phase 2
10 Freund's Adjuvant Phase 2
11 Immunologic Factors Phase 2
12 Anti-Retroviral Agents Phase 2
13 Anti-Infective Agents Phase 2
14 Antiviral Agents Phase 2
15 Anti-HIV Agents Phase 2
16
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
17
Bevacizumab Approved, Investigational Phase 1 216974-75-3
18
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
19 Angiogenesis Inhibitors Phase 1
20 Antineoplastic Agents, Immunological Phase 1
21 Antirheumatic Agents Phase 1
22 Immunosuppressive Agents Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse: Unknown status NCT00660101 Phase 1, Phase 2
2 Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum Completed NCT01583322 Phase 2 vargatef;placebo
3 Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary Terminated NCT00001827 Phase 2
4 A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer Withdrawn NCT03281681 Phase 1, Phase 2 VAL-083, Dianhydrogalactitol
5 Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months Completed NCT02217956 Phase 1 Cisplatin;Bevacizumab
6 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Active, not recruiting NCT03608618 Phase 1 Cyclophosphamide
7 The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas Recruiting NCT04248231

Search NIH Clinical Center for Ovary Adenocarcinoma

Genetic Tests for Ovary Adenocarcinoma

Anatomical Context for Ovary Adenocarcinoma

MalaCards organs/tissues related to Ovary Adenocarcinoma:

40
Ovary, Lymph Node, T Cells, Thyroid, Endothelial, Colon, Cervix

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 1060)
# Title Authors PMID Year
1
Prediction of cancer driver mutations in protein kinases. 6
18339846 2008
2
Folic acid functionalized gold nanoclusters for enabling targeted fluorescence imaging of human ovarian cancer cells. 61
33592715 2021
3
Influence of core extension and side chain nature in targeting G-quadruplex structures with perylene monoimide derivatives. 61
33550073 2021
4
Ovarian adenocarcinoma with metastases in a white rhinoceros. 61
33427119 2021
5
Long-Term Treatment Results for Ovarian Tumors with Malignant Effusion in Seven Dogs. 61
33770181 2021
6
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 61
33568870 2021
7
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. 61
33087508 2021
8
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma. 61
33452985 2021
9
Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma. 61
33049689 2021
10
Comparative Analysis of Cell-Cell Contact Abundance in Ovarian Carcinoma Cells Cultured in Two- and Three-Dimensional In Vitro Models. 61
33291824 2020
11
Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas. 61
33052898 2020
12
Identification and validation of core genes for serous ovarian adenocarcinoma via bioinformatics analysis. 61
32934713 2020
13
Ovarian Carcinoma Uncloaked by Hydatidosis: An Intraoperative Epiphany. 61
33274151 2020
14
Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer. 61
33062161 2020
15
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy. 61
33092037 2020
16
Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature. 61
32483276 2020
17
A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor. 61
32992673 2020
18
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. 61
32451330 2020
19
Breast and Axillary Lymph Node Metastasis from Ovarian Cancer: A Case Report. 61
32750046 2020
20
Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. 61
32807164 2020
21
Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. 61
32776042 2020
22
Gone but Not Forgotten: Ovarian Metastasis From a Colon Carcinoma in a 19-Year-Old Female. 61
32874796 2020
23
Robotic Tumor Debulking off External Iliac Vessels for the Management of Recurrent Ovarian Cancer. 61
31610315 2020
24
Antioxidant, antiproliferative and healing properties of araticum (Annona crassiflora Mart.) peel and seed. 61
32466931 2020
25
A Tertiary Cancer Center Experience of 52 Cases of Primary Ovarian Mucinous Adenocarcinomas. 61
33354551 2020
26
Bevacizumab-induced dysphonia: A case report with brief review of literature. 61
31771464 2020
27
Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines. 61
31241128 2020
28
Identification of Human Ovarian Adenocarcinoma Cells with Cisplatin-resistance by Feature Extraction of Gray Level Co-occurrence Matrix Using Optical Images. 61
32527052 2020
29
Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. 61
32370213 2020
30
Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas. 61
32488223 2020
31
Characterization of ascites-derived aldehyde dehydrogenase-positive ovarian cancer stem cells isolated from Leghorn chickens. 61
32241506 2020
32
MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma. 61
31754782 2020
33
Identification of Radiation-Dose-Dependent Expressive Genes in Individuals Exposed to External Ionizing Radiation. 61
31910119 2020
34
Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base. 61
31839340 2020
35
Stomach gastrin is regulated by sodium via PPAR-α and dopamine D1 receptor. 61
31794424 2020
36
Comparative study of the antitumoral activity of phosphine-thiosemicarbazone gold(I) complexes obtained by different methodologies. 61
31786438 2020
37
The Relationship of FOXR2 Gene Expression Profile with Epithelial-Mesenchymal Transition Related Markers in Epithelial Ovarian Cancer. 61
32683876 2020
38
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. 61
32117253 2020
39
Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation. 61
33061592 2020
40
Extended Pelvic Resections as Part of Secondary Cytoreduction for Relapsed Ovarian Adenocarcinoma. 61
31882505 2020
41
Ovarian adenocarcinoma metastasis mimicking psoas abscess on imaging: a case report. 61
33708322 2020
42
Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. 61
31520887 2019
43
Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin. 61
31817672 2019
44
A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. 61
31246641 2019
45
GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum. 61
31463421 2019
46
Hyperthermia potentiates cisplatin cytotoxicity and negative effects on mitochondrial functions in OVCAR-3 cells. 61
31332716 2019
47
Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. 61
31394747 2019
48
Fabrication of gold-silver core-shell nanoparticles for performing as ultrabright SERS-nanotags inside human ovarian cancer cells. 61
30974419 2019
49
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. 61
31029905 2019
50
Photodynamic Therapy of Ovarian Carcinoma Cells with Curcumin-Loaded Biodegradable Polymeric Nanoparticles. 61
31208085 2019

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ERBB2 NM_004448.3(ERBB2):c.2570A>G (p.Asn857Ser) SNV Likely pathogenic 13880 rs28933370 GRCh37: 17:37881378-37881378
GRCh38: 17:39725125-39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 118124 17 7571720 7590868 Mutation TP53 Ovarian adenocarcinomas

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 TP53 PIK3CA KRAS HRAS ERBB2 BRCA1
2
Show member pathways
13.25 TP53 PIK3CA KRAS HRAS CTNNB1 BRAF
3
Show member pathways
13.04 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
4
Show member pathways
12.99 TP53 PIK3CA KRAS HRAS CTNNB1 BAX
5
Show member pathways
12.96 PIK3CA KRAS HRAS ERBB2 CTNNB1 BRAF
6
Show member pathways
12.91 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
7 12.86 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
8 12.81 TP53 KRAS HRAS ERBB2 BRAF
9
Show member pathways
12.79 PIK3CA KRAS HRAS CTNNB1 BRAF
10
Show member pathways
12.78 TP53 PIK3CA KRAS HRAS ERBB2
11
Show member pathways
12.76 TP53 PIK3CA KRAS HRAS BAX
12
Show member pathways
12.68 TP53 PIK3CA KRAS HRAS ERBB2 BRAF
13
Show member pathways
12.64 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
14
Show member pathways
12.64 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
15
Show member pathways
12.58 TP53 PIK3CA KRAS HRAS ERBB2 BRAF
16
Show member pathways
12.57 TP53 PIK3CA KRAS HRAS CTNNB1
17
Show member pathways
12.57 TP53 PIK3CA KRAS HRAS ERBB2 BRCA1
18
Show member pathways
12.54 PIK3CA KRAS HRAS ERBB2 BAX
19
Show member pathways
12.48 PIK3CA KRAS HRAS CTNNB1 BRCA1 BRAF
20
Show member pathways
12.45 PIK3CA KRAS HRAS BRAF
21
Show member pathways
12.45 PIK3CA KRAS HRAS ERBB2 CTNNB1 BRAF
22
Show member pathways
12.44 TP53 PIK3CA HRAS BAX
23
Show member pathways
12.42 TP53 MIR17 BRCA1 BAX
24 12.41 TP53 PIK3CA KRAS HRAS BAX
25
Show member pathways
12.4 TP53 PIK3CA HRAS ERBB2 CTNNB1 BAX
26
Show member pathways
12.4 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
27 12.37 TP53 PIK3CA KRAS HRAS BAX
28
Show member pathways
12.35 TP53 KRAS HRAS BRAF
29 12.35 TP53 PIK3CA MIR30A MIR17 KRAS HRAS
30
Show member pathways
12.34 PIK3CA KRAS HRAS ERBB2
31
Show member pathways
12.34 PIK3CA KRAS HRAS ERBB2 CTNNB1 BRAF
32
Show member pathways
12.32 PIK3CA KRAS HRAS BRAF
33
Show member pathways
12.28 PIK3CA KRAS HRAS CEACAM5
34
Show member pathways
12.28 TP53 PIK3CA KRAS HRAS ERBB2 BRAF
35 12.27 TP53 KRAS CTNNB1 BRAF BAX
36
Show member pathways
12.26 TP53 PIK3CA KRAS HRAS BRAF
37 12.24 KRAS HRAS ERBB2 BRAF
38
Show member pathways
12.23 TP53 KRAS HRAS BRAF BAX
39
Show member pathways
12.22 TP53 PIK3CA KRAS HRAS BAX
40 12.21 TP53 PIK3CA KRAS HRAS
41
Show member pathways
12.19 PIK3CA KRAS HRAS ERBB2
42 12.19 PIK3CA KRAS INHBA HRAS CTNNB1
43 12.18 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
44
Show member pathways
12.14 PIK3CA KRAS HRAS BRAF
45 12.12 TP53 KRAS CTNNB1 BRCA1 BRAF BAX
46 12.11 TP53 PIK3CA KRAS HRAS CTNNB1
47 12.1 TP53 PIK3CA KRAS HRAS BAX
48
Show member pathways
12.09 TP53 PIK3CA ERBB2 BRAF
49
Show member pathways
12.09 PIK3CA HRAS CTNNB1 BRAF
50 12.05 TP53 KRAS HRAS CTNNB1 BRAF

GO Terms for Ovary Adenocarcinoma

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.89 TP53 INHBA HRAS CTNNB1 BAX
2 regulation of cell proliferation GO:0042127 9.78 TP53 CTNNB1 BRCA1 BRAF
3 nervous system development GO:0007399 9.73 INHBA ESS2 ERBB2 CTNNB1 BAX ARID1A
4 Ras protein signal transduction GO:0007265 9.69 TP53 KRAS HRAS
5 positive regulation of MAP kinase activity GO:0043406 9.61 KRAS HRAS ERBB2
6 positive regulation of neuron apoptotic process GO:0043525 9.58 TP53 CTNNB1 BAX
7 response to salt stress GO:0009651 9.52 TP53 BAX
8 response to isolation stress GO:0035900 9.46 KRAS HRAS
9 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902108 9.37 TP53 BAX
10 negative regulation of neuron apoptotic process GO:0043524 9.35 PIK3CA KRAS HRAS BRAF BAX
11 intrinsic apoptotic signaling pathway GO:0097193 9.33 TP53 HRAS BAX
12 cellular response to indole-3-methanol GO:0071681 9.32 CTNNB1 BRCA1
13 positive regulation of gene expression GO:0010628 9.23 TP53 KRAS INHBA HRAS ERBB2 CTNNB1

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 TP53 KRAS INHBA ERBB2 CEACAM5 BRCA1

Sources for Ovary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....